Movement Alert｜Hengrui Medicine Rises 3.47% in Regular Trading, First Self-Developed Innovative Drug Marketing Application Accepted by EMA

Market Focus06-24 09:44

On June 24, Hengrui Medicine (01276.HK) rose 3.47% in regular trading, trading at HK$57.9/share, with turnover of HK$26.10 million. The stock continued its upward momentum following a 3.73% gain in the previous session.

On the news front, the European Medicines Agency officially accepted the company's marketing authorization application for revulutamide tablets, marking the first self-developed innovative drug submitted by Hengrui Medicine for EU market approval. The drug is indicated for use in combination with androgen deprivation therapy for the treatment of adult male patients with high tumor burden metastatic hormone-sensitive prostate cancer, representing a substantial milestone in the company's internationalization strategy.

Meanwhile, the innovative drug sector broadly strengthened, with multiple Hong Kong-listed pharmaceutical stocks rising in tandem, creating a visible sector linkage effect. Within the Pharmaceuticals sector, ASYMCHEM gained 7.23%, Shandong Xinhua rose 3.67%, SBP Group advanced 2.52%, CSPC Pharma added 1.35%, and Hansoh Pharma climbed 1.08%.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1192624255?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-24 09:44","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1192624255","market":"hk","top_or_hot":-1,"title":"Movement Alert｜Hengrui Medicine Rises 3.47% in Regular Trading, First Self-Developed Innovative Drug Marketing Application Accepted by EMA","media":"Market Focus","content":"<p><p>On June 24, Hengrui Medicine (01276.HK) rose 3.47% in regular trading, trading at HK$57.9/share, with turnover of HK$26.10 million. The stock continued its upward momentum following a 3.73% gain in the previous session.</p><p>On the news front, the European Medicines Agency officially accepted the company's marketing authorization application for revulutamide tablets, marking the first self-developed innovative drug submitted by Hengrui Medicine for EU market approval. The drug is indicated for use in combination with androgen deprivation therapy for the treatment of adult male patients with high tumor burden metastatic hormone-sensitive prostate cancer, representing a substantial milestone in the company's internationalization strategy.</p><p>Meanwhile, the innovative drug sector broadly strengthened, with multiple Hong Kong-listed pharmaceutical stocks rising in tandem, creating a visible sector linkage effect. Within the Pharmaceuticals sector, ASYMCHEM gained 7.23%, Shandong Xinhua rose 3.67%, SBP Group advanced 2.52%, CSPC Pharma added 1.35%, and Hansoh Pharma climbed 1.08%.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Hengrui Medicine Rises 3.47% in Regular Trading, First Self-Developed Innovative Drug Marketing Application Accepted by EMA</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Hengrui Medicine Rises 3.47% in Regular Trading, First Self-Developed Innovative Drug Marketing Application Accepted by EMA\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-06-24 09:44</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On June 24, Hengrui Medicine (01276.HK) rose 3.47% in regular trading, trading at HK$57.9/share, with turnover of HK$26.10 million. The stock continued its upward momentum following a 3.73% gain in the previous session.</p><p>On the news front, the European Medicines Agency officially accepted the company's marketing authorization application for revulutamide tablets, marking the first self-developed innovative drug submitted by Hengrui Medicine for EU market approval. The drug is indicated for use in combination with androgen deprivation therapy for the treatment of adult male patients with high tumor burden metastatic hormone-sensitive prostate cancer, representing a substantial milestone in the company's internationalization strategy.</p><p>Meanwhile, the innovative drug sector broadly strengthened, with multiple Hong Kong-listed pharmaceutical stocks rising in tandem, creating a visible sector linkage effect. Within the Pharmaceuticals sector, ASYMCHEM gained 7.23%, Shandong Xinhua rose 3.67%, SBP Group advanced 2.52%, CSPC Pharma added 1.35%, and Hansoh Pharma climbed 1.08%.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01276","symbol_name":"恒瑞医药","start_time":0,"source_url":"","article_id":"1192624255","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1192624255","pubTimestamp":1782265476,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On June 24, Hengrui Medicine (01276.HK) rose 3.47% in regular trading, trading at HK$57.9/share, with turnover of HK$26.10 million. The stock continued its upward momentum following a 3.73% gain in...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01276":"恒瑞医药"},"translate_title":"动静快讯|恒瑞医药常规交易涨3.47%首个自研创新药上市申请获EMA受理","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01276":1},"content_text":"On June 24, Hengrui Medicine (01276.HK) rose 3.47% in regular trading, trading at HK$57.9/share, with turnover of HK$26.10 million. The stock continued its upward momentum following a 3.73% gain in the previous session.On the news front, the European Medicines Agency officially accepted the company's marketing authorization application for revulutamide tablets, marking the first self-developed innovative drug submitted by Hengrui Medicine for EU market approval. The drug is indicated for use in combination with androgen deprivation therapy for the treatment of adult male patients with high tumor burden metastatic hormone-sensitive prostate cancer, representing a substantial milestone in the company's internationalization strategy.Meanwhile, the innovative drug sector broadly strengthened, with multiple Hong Kong-listed pharmaceutical stocks rising in tandem, creating a visible sector linkage effect. Within the Pharmaceuticals sector, ASYMCHEM gained 7.23%, Shandong Xinhua rose 3.67%, SBP Group advanced 2.52%, CSPC Pharma added 1.35%, and Hansoh Pharma climbed 1.08%.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1192624255","isCrawlerRequest":true}